Treatment of Rheumatoid Arthritis with Oral Type II Collagen.
- Author:
Yeon Sik HONG
1
;
Wan Uk KIM
;
Shin Seok LEE
;
Yeong Sil ZOO
;
Jun Ki MIN
;
Sung Hwan PARK
;
Sang Heon LEE
;
Chul Soo CHO
;
Ho Youn KIM
Author Information
1. Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Rheumatoid Artiritis (RA);
Type II collagen;
Oral tolerance
- MeSH:
Administration, Oral;
Antibodies;
Arthritis, Rheumatoid*;
Autoimmunity;
Collagen Type II*;
Humans;
Immunoglobulin G;
Joints;
Urticaria
- From:The Journal of the Korean Rheumatism Association
1999;6(2):149-156
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To investigate the efficacy and safety of oral bovine type II collagen (C II) in the treatment of rheumatoid arthritis (RA). METHODS: Forty-five patients with active RA were enrolled and randomized to receive placebo or oral C II for 3 months. Efficacy parameters were assessed monthly. Cumulative response rates (percentages of patients meeting the criteria for response at anytime during the study) were analyzed utilizing 3 set of composite criteria : Paulus criteria, ACR criteria for improvement in RA, and a requirement for > or = 30% reduction in both swollen and tender joint counts. RESULTS: The C II-treated group (n=25) showed significant higher response rate by the Paulus criteria compared to placebo group (n=20, p=0.04), and MHAQ scores between baseline and 3 months of treatment were also significantly decreased in the C II-treated group (p<0.05). However, there were no significant differences in tender and swollen joint count, and physician and patient global scores between C II-treated and placebo groups. Only one patient treated with C II had a urticaria 1 week after administration, but no serious side effects were found in the two groups. Patients treated with C II (n=15) showed the decreased levels of circulating IgG antibodies to bovine C II 3 months after treatment (p=0.02), whereas significant changes of IgG antibodies to C II were not found in placebo group (n=12). CONCLUSION: Oral administration of C II was safe and effective for the treatment of rheumatoid arthritis. The finding that serum IgG antibodies to bovine C II was decreased in patients who treated with C II suggest that autoimmune response to C II could be decreased by repetitive administration of C II.
